

IMI 2 Open Info Day 2014

Agenda

30.09.2014 • Crowne Plaza Brussels - Le Palace
Rue Gineste 3, 1210 Brussels • Belgium

08:30 - 09:30 *Registration & networking breakfast*

09:30 - 10:30 **Plenary Session - Ballroom**

Welcome

Michel Goldman, Executive Director, IMI

Industry perspective on IMI 2

Magda Chlebus, Director, Science Policy, EFPIA

Commission perspective on IMI 2

Ruxandra Draghia-Akli, Director, Directorate Health, DG Research and Innovation, European Commission

10:30 - 11:00 *Coffee break*

11:00 - 12:30 **IMI 2 Call procedures - Ballroom**

Overview of rules and procedures

Magali Poinot, Legal Manager, IMI

Tips for applicants

Hugh Laverty, Senior Scientific Project Manager, IMI

Roundtable Questions & Answers

Moderated by Michel Goldman, Executive Director, IMI

12:30 - 14:00 *Networking Lunch*

14:00 - 16:00 **Parallel Workshops - IMI 2 Call 1 Topics**

Workshop A - Ballroom

Translational approaches to disease modifying therapy of type 1 diabetes mellitus

Presented by Anke Schulte, Research & Translational Medicine, Sanofi-Aventis

Moderated by Magda Gunn, Scientific Project Manager, IMI

Networking elevator pitches by participants*

Workshop B - Klimt Room

Discovery and validation of novel endpoints in retinal diseases

Presented by Oliver Zeitz, Global Clinical Development Ophthalmology, Bayer

Moderated by Nathalie Seigneuret, Senior Scientific Project Manager, IMI

Networking elevator pitches by participants*

16:00 - 16:30 *Coffee break*

* During the topic workshops, participants will have the opportunity to deliver a 90-second 'elevator pitch' to advertise their expertise to potential project partners. If you would like to give an elevator pitch, please indicate this when registering for your workshop.

16:30 - 17:30

IMI 2 Call 2 – Indicative Call Topics – Ballroom

RADAR Remote assessment of disease and relapse

Theo Meert, Senior Director External Innovations NS, Janssen Research & Development, J&J

Assessing risk and progression of pre-diabetes and type 2 diabetes to enable disease modification

Bernd Stowasser, Head of European Public Partnerships, Sanofi-Aventis

**Towards a quantitative biological approach for neuropsychiatry
Overview – EFPIA Representative**

Hugh Marsten, Head of In Vivo Pharmacology, Eli Lilly

Questions & Answers

Moderated by Elisabetta Vaudano, Scientific Pillar Coordinator, IMI

17:30 - 18:30

Farewell networking coffee break